About Myocilin
Myocilin (MYOC) is a protein
from Homo sapiens identified by UniProt accession
Q99972, 504 residues long.
MolForge cross-references it against 0 known binders and
147 disease associations.
Target properties
| Protein name | Myocilin |
| UniProt accession | Q99972 |
| Gene | MYOC |
| Organism | Homo sapiens |
| Length | 504 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (147)
Diseases linked to this target (Open Targets).
- glaucoma 1, open angle, A · score 0.83
- Juvenile glaucoma · score 0.83
- glaucoma · score 0.68
- juvenile open angle glaucoma · score 0.67
- open-angle glaucoma · score 0.65
- platelet component distribution width · score 0.50
- congenital glaucoma · score 0.38
- intraocular pressure measurement · score 0.37
- response to xenobiotic stimulus · score 0.31
- Abnormality of T cell physiology · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99972-F1 | alphafold | PREDICTED | 78.92 | — |
Amino-acid sequence (504 residues)
MRFFCARCCS FGPEMPAVQL LLLACLVWDV GARTAQLRKA NDQSGRCQYT FSVASPNESS CPEQSQAMSV IHNLQRDSST QRLDLEATKA RLSSLESLLH QLTLDQAARP QETQEGLQRE LGTLRRERDQ LETQTRELET AYSNLLRDKS VLEEEKKRLR QENENLARRL ESSSQEVARL RRGQCPQTRD TARAVPPGSR EVSTWNLDTL AFQELKSELT EVPASRILKE SPSGYLRSGE GDTGCGELVW VGEPLTLRTA ETITGKYGVW MRDPKPTYPY TQETTWRIDT VGTDVRQVFE YDLISQFMQG YPSKVHILPR PLESTGAVVY SGSLYFQGAE SRTVIRYELN TETVKAEKEI PGAGYHGQFP YSWGGYTDID LAVDEAGLWV IYSTDEAKGA IVLSKLNPEN LELEQTWETN IRKQSVANAF IICGTLYTVS SYTSADATVN FAYDTGTGIS KTLTIPFKNR YKYSSMIDYN PLEKKLFAWD NLNMVTYDIK LSKM
Explore Myocilin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets